Gianluca Rigatelli, MD; Gabriele Braggion, MD; Silvio Aggio, MD; Mauro Chinaglia, MD; Paolo Cardaioli, MD
Potential Financial Conflicts of Interest: None disclosed.
Rigatelli G., Braggion G., Aggio S., Chinaglia M., Cardaioli P.; Primary Patent Foramen Ovale Closure To Relieve Severe Migraine. Ann Intern Med. 2006;144:458-460. doi: 10.7326/0003-4819-144-6-200603210-00028
Download citation file:
Published: Ann Intern Med. 2006;144(6):458-460.
TO THE EDITOR:
Background: Migraine headaches are highly prevalent in the general population and account for significant morbidity, lost productivity, health care visits, and dollars spent. The prevalence of migraine headaches is higher in patients with patent foramen ovale (PFO), which causes paradoxical embolism and cryptogenic stroke, than in the general population (1). Previous studies have suggested that closure of the PFO may reduce or resolve migraine symptoms (2, 3). Currently, percutaneous transcatheter closure of PFO is reserved for patients with recurrent migraine headaches who have a history of stroke (3, 4).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only